Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 14;28(6):689-692.
doi: 10.3748/wjg.v28.i6.689.

Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

Jian-Guo Hong  1 , Lun-Jie Yan  1 , Xian Li  1 , Sheng-Yu Yao  1 , Peng Su  2 , Hai-Chao Li  1 , Zi-Niu Ding  1 , Dong-Xu Wang  1 , Zhao-Ru Dong  1 , Tao Li  3
Affiliations

Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

Jian-Guo Hong et al. World J Gastroenterol. .

Abstract

To evaluate and predict liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), several non-invasive scoring systems were built and widely used in the progress of diagnosis and treatment, which showed great diagnostic efficiency, such as aspartate aminotransferase to platelet ratio index, fibrosis-4 index, body mass index, aspartate aminotransferase to alanine aminotransferase ratio, diabetes score and NAFLD fibrosis score. Since the new concept of metabolic associated fatty liver disease (MAFLD) was proposed, the clinical application value of the non-invasive scoring systems mentioned above has not been assessed in MAFLD. The evaluation of the diagnostic performance of these non-invasive scoring systems will provide references for clinicians in the diagnosis of MAFLD.

Keywords: Calibration; Metabolic associated fatty liver disease; Nonalcoholic fatty liver disease; Normal distribution; Prediction model.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors have no conflicts of interest to disclose.

References

    1. Wu YL, Kumar R, Wang MF, Singh M, Huang JF, Zhu YY, Lin S. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27:5753–5763. - PMC - PubMed
    1. Nielsen MJ, Leeming DJ, Goodman Z, Friedman S, Frederiksen P, Rasmussen DGK, Vig P, Seyedkazemi S, Fischer L, Torstenson R, Karsdal MA, Lefebvre E, Sanyal AJ, Ratziu V. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. J Hepatol. 2021;75:1292–1300. - PubMed
    1. Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, Delfino K, Fan Y, Zhao Z, Koyama T, Hollenbeck B, Qin R, Zahnd W, Zabor EC, Kattan MW, Vickers AJ. Guidelines for Reporting of Statistics for Clinical Research in Urology. Eur Urol. 2019;75:358–367. - PMC - PubMed
    1. Monaghan TF, Rahman SN, Agudelo CW, Wein AJ, Lazar JM, Everaert K, Dmochowski RR. Foundational Statistical Principles in Medical Research: Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value. Medicina (Kaunas) 2021;57 - PMC - PubMed
    1. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr. 2007;96:487–491. - PubMed

MeSH terms